RxDoctor Payments Data

Brandy Barrett

Psychiatric/Mental Health · Chestertown, MDNPI 1699316950

Payments from drug & device makers

$2,605in general payments, 2019–2025

Across 140 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$720
  • Neurocrine Biosciences, Inc.$408
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$397
  • Teva Pharmaceuticals USA, Inc.$263
  • Otsuka America Pharmaceutical, Inc.$184
  • Johnson & Johnson$169
  • plus $465 from 7 others

What the payments were for

  • Food & beverage$2,50896%
  • Education$974%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,605 in reported general payments places this provider in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

See all psychiatric/mental health providers in Maryland

Medicare billing

Part B allowed, 2024
$33,269
Medicare patients
31
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$156,457
Invega SustennaPaliperidone Palmitate14$39,836
Abilify MaintenaAripiprazole12$34,951
VraylarCariprazine Hcl22$34,673
Risperdal ConstaRisperidone Microspheres14$18,139
Lurasidone Hcl38$16,734
Methylphenidate Er (La)Methylphenidate Hcl12$1,926
Oxcarbazepine43$1,920
Bupropion XlBupropion Hcl63$1,643
Desvenlafaxine Succinate ErDesvenlafaxine Succinate39$1,227
Haloperidol Decanoate26$1,114
Fluvoxamine Maleate26$942
Clozapine12$742
Hydroxyzine Pamoate41$734
Buspirone Hcl45$723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$408$156,45718 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$169$57,97428 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$184$34,95112 claims
AbbVieVraylar$720$34,67322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,461 psychiatric/mental health providers in Maryland.

Other psychiatric/mental health in Chestertown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →